Newborn Drug Testing

Untitled Document

Timely detection of in utero drug exposure is critical for effective detection and management of intoxication, withdrawal syndrome, and long-term needs (social and medical) for exposed neonates. Two modes of testing are available: umbilical cord tissue and meconium.



Chain-of-custody may not be required:

Umbilical cord and meconium drug tests are performed to support clinical and social management decisions, and do not usually require chain-of-custody.

If chain-of-custody is required, ARUP will provide you a form, or will honor an external form. Contact ARUP Client Services for more information.


Meconium

ARUP Test Code 0092516

Meconium is the traditional specimen to detect and document maternal drug use during pregnancy, approximately the last trimester of a full-term birth. ARUP’s neonatal drug testing in meconium is a qualitative immunoassay screen for nine drug classes. Specimens testing positive for one or more drugs are reflexed to highly sensitive and specific mass spectrometry technology for confirmation.

Drugs and Drug Metabolites Reported

Opioids Stimulants Sedatives/Hypnotics Other

buprenorphine
norbuprenorphine
methadone
methadone metabolite (EDDP)
heroin metabolite
(6-acetylmorphine)
morphine
codeine
hydromorphone
hydrocodone
oxycodone
oxymorphone

methamphetamine
amphetamine
MDA
MDEA (Eve)
MDMA (Ecstasy)
cocaine
cocaine metabolites:
benzoylecgonine
m-hydroxybenzoylecgonine
cocaethylene

alprazolam
a-hydroxyalprazolam
butalbital
clonazepam
7-amino clonazepam
diazepam
nordiazepam
oxazepam
temazepam
lorazepam
midazolam
phenobarbital

cannabis (THC) metabolite
phencyclidine (PCP)


Umbilical Cord Tissue

Test Number Test Name
2006621 Drug Detection Panel, Umbilical Cord Tissue, Qualitative
3000256 Marijuana Metabolite, Umbilical Cord Tissue, Qualitative
3000443 Ethyl Glucuronide, Umbilical Cord Tissue, Qualitative

Umbilical cord tissue is a relatively new specimen to detect and document maternal drug use during pregnancy, approximately the last trimester of a fullterm birth. ARUP’s neonatal drug testing in umbilical cord tissue is based on highly sensitive and specific qualitative liquid chromatography and tandem mass spectrometry (LC-MS/MS) .

Drugs and Drug Metabolites Reported in Drug Detection Panel, Umbilical Cord Tissue, Qualitative (2006621)

Opioids Stimulants Sedatives/Hypnotics Other

​buprenorphine
norbuprenorphine
buprenorphine glucuronide
methadone
methadone metabolite (EDDP)
heroin metabolite
(6-acetylmorphine)
morphine
codeine
dihydrocodeine
hydrocodone
norhydrocodone
hydromorphone
oxycodone
noroxycodone
oxymorphone
noroxymorphone
tramadol
n-desmethyl tramadol
o-desmethyl-tramadol
tapentadol
meperidine
fentanyl
propoxyphene
naloxone​

methamphetamine
amphetamine
MDMA (Ecstasy)
cocaine
cocaine metabolites:
benzoylecgonine
m-hydroxybenzoylecgonine
cocaethylene
phentermine

7-amino clonazepam
a-hydroxyalprazolam
a-hydroxymidazolam
alprazolam
butalbital
clonazepam
diazepam
lorazepam
midazolam
nordiazepam
oxazepam
phenobarbital
temazepam
zolpidem

phencyclidine (PCP)


Additional Resources

Expertise

  • Medical Director, Toxicology Laboratory and Pharmacogenetics
    Dr. Dr. McMillin is a professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. She is a member of ARUP’s R&D Executive Committee, and is actively involved in professional associations such as the International Association of Therapeutic Drug Monitoring and Clinical Chemistry (IATDMCT), the American Association for Clinical Chemistry (AACC), and the College of American Pathologists (CAP). Her primary interests include detection of neonatal drug exposures, pain management, and clinical applications and implementation of pharmacogenomics.